A 51 year old South Asian woman was referred by her GP to the outpatient endocrine clinic with diffuse musculosksletal pains in her lower limbs, lethargy and weight gain in the context of a previous hemithyroidectomy 
Social history
Works in customer services 2 school-age children
Further history of presenting complaint
Further history revealed intermittent pains in both lower limbs for several months; primarily left knee and right ankle. This was associated with 5kg of unintentional weight gain.. The patient also had a new diagnosis with hypercholesterolaemia from her GP 9 months ago that was being managed with lifestyle interventions in the first instance. She reported feeling increasingly lethargic for many months but this hasn't affected her ability to undertake her job or activities of daily living 
Diagnosis and management
Diagnosis: Panhypopituitarism with a metabolic myositis and dyslipidaemia Commenced on thyroid hormone replacement which was subsequently uptitrated to 100 micrograms per day and hydrocortisone replacement therapy (10mg, 5mg, 5mg)
Over the following 9-12 months there was almost a complete resolution of the metabolic myositis and dyslipidaemia as shown on the graphs below Subsequently, the patient experienced exertional chest pains prompting a cardiology referral. Work-up has revealed stenosis within the LAD awaiting percutaneous intervention.
Hypothyroid myositis Hypothyroid dyslipidaemia TSH and T4 -paired testing
This patient demonstrates a mild hypothyroid myositis with gradual normalisation of CK upon initiation of exogenous thyroid hormone. Musculoskeletal complaints are very common in patients with hypothyroidism; up to 79% as reported by Duyff and colleagues in a prospective cohort study although only 38% had clinical signs of weakness. [1] Elevation of serum CK is also common in hypothyroidism with between 37%-60% having values above the upper limit of the reference range [2] . There is a poor correlation between the extent of the rise of the CK and clinical symptomology (both subjective and objective). Generally, a CK >10 times the upper limit of normal (~2000iU/L) is thought to be of clinical significance and warrant further investigation or therapy rather than just monitoring. Without a clear aetiology for the hyperCKaemia a serum TSH would always be advised to screen for thyroid dysfunction.The pathophysiology underlying the muscle changes in hypothyroidism are well documented. Lack of bioavailable T3 leads to intracellular changes in glycogen metabolism and oxidative phosphorylation and alterations of the actin-myosin unit. Ultrastructurally changes are also seen in the membrane permeability of myocytes leading to increased enzymatic release. [2] Dyslipidaemia is a common abnormality in patients with thyroid disease. It is the end result of thyroid hormones playing a role in multiple aspects of lipid metabolism including synthesis, mobilisation and degradation. The most common pattern of lipid abnormalities seen in overt hypothyroidism is an increase in total cholesterol and in LDLcholesterol. Triglycerides, HDL-cholesterol and lipoprotein may either be normal or mildly elevated. The case presented here is in-keeping with the literature. [4] Patients with overt hypothyroidism are at significantly increased risk of cardiovascular disease. Due to the wideranging effects of thyroid hormones this is multifactorial. Hypothyroidism has been shown to accelerate plaque development, directly impair left ventricular function and increase total peripheral resistance. The effect of atherosclerosis is independent of the effect on lipid profile. [4] There is little in the literature to quantify the increased risk of overt hypothyroid on cardiovascular outcomes. However, metaanalyses of cohort studies have shown sub-clinical hypothyroidism gives a relative risk of 1.21 for all-cause cardiovascular mortality in those aged <65. [5] The risk from overt hypothyroidism is likely even greater. I suspect hypothyroidism played a significant role in the development of this patient's early ischaemic heart disease given that she has few other conventional risk factors.
In 2006 guidelines were published by the British Thyroid Society summarising recommendations with regards to the biochemical diagnosis and monitoring of thyroid disorders. [3] It is noted that the strategy of first-line measurement of TSH alone is only cost effective for the purposes of screening and is inappropriate in certain clinical situations. TSH monitoring alone would be considered appropriate post-thyroidectomy in an asymptomatic patient. However, in the context of the signs, symptoms and biochemical abnormalities that could be precipitated by derangement of the thyroid axis, paired-testing should always performed. The combination of weight-gain, new severe dyslipidaemia and metabolic myositis with no other clear precipitant should have prompted paired testing earlier on in the case. Thyroid hormone replacement 18-24 months earlier could have assuaged a significant burden or cardiovascular risk.
